Latest research on Desvenlafaxine

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Desvenlafaxine indications

UKU scale is used to evaluate side effects and the values are (0.93 and 1.13), respectively in Escitalopram and Desvenlafaxine group. [source, 2016]
Similar side effect profile was put forth by Soares et al.,[14] who showed both Desvenlafaxine and Escitalopram were generally safe and well-tolerated. [source, 2016]
To our knowledge, no study examining the effects of Desvenlafaxine (O-desmethylvenlafaxine), the major active metabolite of venlafaxine [326], in PD or animal models of PD has been published. [source, 2015]
Therefore, this study was undertaken to compare the clinical effectiveness and safety of Desvenlafaxine versus the standard antidepressant, Escitalopram in patients with MDD associated with symptoms of anxiety. [source, 2014]
Since the 50% responder rate were similar in both the groups in the follow-up visits, Escitalopram and Desvenlafaxine have comparable effectiveness in controlling symptoms of anxiety with depression. [source, 2014]
In terms of tolerability, Escitalopram was better tolerated than Desvenlafaxine, as Escitalopram indicated lesser incidence of adverse effects. [source, 2014]
The findings of the primary studies on Desvenlafaxine effectiveness and safety in the treatment of menopausal vasomotor symptoms were inconclusive. [source, 2014]
A systematic review of four clinical trials pointed out that the Desvenlafaxine treatment on hot flashes has inconsistent effectiveness results (33). [source, 2014]
Above all, although several statistically significant side effects were identified, a wrong conclusion was made by stating that Desvenlafaxine appears safe (34). [source, 2014]
The predefined inclusion criteria were: 1) double-blind randomized controlled studies that weighted the effectiveness and safety of Desvenlafaxine against placebo in postmenopausal women who were seeking treatment for hot flashes and/or who experienced at least 7 moderate to severe hot flashes per day; and 2) studies that were published in English and have a duration of therapy not less than 12 weeks. [source, 2014]